Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2020 and Year Ending March 31, 2021
August 06, 2020 at 12:00 am EDT
Share
Sawai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the period ending September 2020 and year ending March 31, 2021. For the period ending September 2020, the company expects sales of JPY 96,000 million, operating profit of JPY 13,350 million, profit attributable to owners of parent of JPY 9,950 million and basic earnings per share of JPY 227.26.
For the year ending March 31, 2021, the company expects sales of JPY 200,200 million, operating profit of JPY 26,850 million, profit attributable to owners of parent of JPY 20,050 million and basic earnings per share of JPY 457.94.
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
SAWAI GROUP HOLDINGS CO., LTD. 
